Tag
Anupam Rasayan India Limited
8 articles
Anupam Rasayan India Limited is significantly reshaping its business profile through the acquisition of Bliss GVS Pharma, creating a ₹4,000+ crore integrated platform with expanded capabilities in finished dosage formulations. The transaction, financed through a combination of debt and non-voting instruments from investors like Bain Capital, grants Anupam Rasayan control of Bliss GVS, including six FDA/EU-GMP certified plants. While the open offer to acquire a 26% stake yielded a minimal response, the core acquisition remains on track, though regulatory approvals and shareholder votes are still pending. Investors should monitor the integration of Bliss GVS and the impact on Anupam Rasayan’s overall financial performance and market position.
Anupam Rasayan Clarifies Bliss GVS Pharma Acquisition Details
Anupam Rasayan issues clarification correcting typographical errors in its previous disclosure regarding acquisition of Bliss GVS Pharma shares.
Confirms PAC acquired 5,09,84,595 equity shares represe
Anupam Rasayan 23rd AGM Approves Dividend and Results
Anupam Rasayan held its 23rd Annual General Meeting on September 30, 2026, via video conference to seek shareholder approval on key resolutions.
Members approved the adoption of audited standalone and
Anupam Rasayan Acquires 50.07% Control of Bliss GVS
Anupam Rasayan completed its acquisition of 50.07% stake in Bliss GVS Pharma, gaining control and promoter status effective 28 September 2026.
The total acquisition cost was INR 162.74 crore for 5.09
Bliss GVS Promoters Reclassified to Public Category
Board approved reclassification of 27 promoter group entities to public category post takeover completion.
Anupam Rasayan India Limited acquired control via share purchase agreement and open offer.
To
Bliss GVS Pharma Control Transfers to Anupam Rasayan
Anupam Rasayan-led consortium acquires 47.95% stake and control of Bliss GVS Pharma, effective September 28, 2026.
Board appoints three new Non-Executive Non-Independent Directors from the acquiring g
Anupam Rasayan Acquires Bliss GVS Pharma for ₹299/Share
Anupam Rasayan completes acquisition of 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share through subsidiary Mates Visa Consultancy.
Transaction funded by ₹300 crore term loan and ₹1,450 c
Anupam Rasayan Bliss GVS Open Offer 1,669 Shares Acquired
Anupam Rasayan India Limited's open offer for 26% of Bliss GVS Pharma concluded with only 1,669 shares tendered and accepted, a tiny fraction of the 2.77 crore shares offered.
The acquirer paid ₹299 p
Bliss GVS Open Offer Addendum Adds Mates Visa as PAC
Bliss GVS Pharma received an addendum to an open offer from Anupam Rasayan, designating Mates Visa Consultancy as a person acting in concert (PAC).
The addendum, dated July 17, 2026, discloses Mates V